APA Annual Meeting
`Date/Place: May 14-18, 2016': / Atlanta
`Abstract submission deadline: December 9, 2015 (midnight EST)
`
`https://ww3.aievolution.com/apalGOl/files/content/docs/GUIDE_How_to_Submit_a_Poster_for_upload_AS.pdf
`
`Maximum number of characters, title: 150 (including spaces) / current characters: 98
`Maximum number of characters, abstract: 3,000 (including spaces) / current characters: 2,989
`
`COST SAVINGS ASSOCIATED WITH IMPROVED ADHERENCE AMONG PATIENTS WITH SCHIZOPHRENIA USING
`LURASIDONE
`
`Daisy S. Ng—Mak, Pth, Ken O'Day, PhD, MPAZ, Chien—Chia Chuang, Pth, Michelle L. Friedman, MPHZ, Kitty Rajagopalan,
`Pth, Antony Loebel, MD3
`
`1Sunovion Pharmaceuticals Inc., Marlborough, MA; 2Xcenda, Palm Harbor, Florida; 3Sunovion Pharmaceuticals Inc., Fort
`Lee, NJ
`
`Background: Schizophrenia, a chronic, severe, and disabling brain and behavior disorder, poses a significant economic
`burden on payers and society. Atypical antipsychotics are standard of care for schizophrenia; however, poor medication
`adherence may limit their effectiveness and adversely affect subsequent outcomes.
`
`Objective: To estimate outcomes and cost offsets of lurasidone associated with improved adherence compared to other
`atypical antipsychotics among patients with schizophrenia from Medicaid and societal perspectives in the United States
`(US).
`
`Methods: An analytic model was developed to estimate the 3-year healthcare resource utilization and outcomes
`(hospitalization, emergency psychiatric services use, arrests, violence, victim of crime, and substance use) and
`associated costs among adult patients with schizophrenia receiving lurasidone, aripiprazole, olanzapine, quetiapine,
`risperidone, and ziprasidone. Adherence data during the 6~month post treatment initiation period were obtained from a
`retrospective claims database studyi; healthcare resource utilization and outcomes data were from a prospective US
`Schizophrenia Care and Assessment Program studyl. Costs of outcomes were obtained from publicly available sources
`and adjusted to 2015 US dollars. Costs per atypical antipsychotic were calculated and then extrapolated across a
`Medicaid plan population of patients with schizophrenia prescribed atypical antipsychotics. The effect of parameter
`uncertainty on model outcomes was evaluated utilizing a probabilistic sensitivity analysis.
`
`Results: Due to greater adherence with lurasidone, the model predicted the use of lurasidone resulted in better
`outcomes (hospitalizations 19.5% vs 21.0%—21.6%; emergency psychiatric services use 8.1% vs 8.6%—8.9%; arrests 5.2%
`vs 5.7%—5.9%; violence 7.4% vs 8.2%—8.5%; victim of crime 11.2% vs 12.2%—12.5%; substance use 24.5% vs 25.4%—25.7%)
`and resulted in per-patient savings of $401, $285, $342, $359, and $396 over 3 years, respectively, compared to
`aripiprazole, olanzapine, quetiapine, risperidone, and ziprasidone . The primary driver of cost savings was the reduction
`in hospitalizations and victim of crime. In a Medicaid plan with 10,000 atypical antipsychotic users where the utilization
`of lurasidone increased from 10% to 20%, total predicted cost savings were $343,365 over 3 years. In the probabilistic
`sensitivity analysis, similar cost savings were observed and lurasidone was the least costly treatment in 99.8% of the
`simulations.
`
`Conclusions: in this assessment, lurasidone was associated with reduced healthcare resource utilization, improved
`outcomes, and cost savings compared to other atypical antipsychotics due to improved adherence.
`
`References:
`
`1. Hassan M et al. Comparison of treatment adherence among adults with schizophrenia on lurasidone vs other
`atypical antipsychotics in a Medicaid population. Poster presented at 2013 USPMHC.
`2. Ascher—Svanum et al. J Clin Psychiatry 2006;67(3): 453—460.
`
`CONFIDENTIAL
`
`1
`
`LATUDAO4345462
`
`Exhibit 2088
`
`Slayback v. Sumitomo
`|PR2020-01053
`
`1
`
`Exhibit 2088
`Slayback v. Sumitomo
`IPR2020-01053
`
`

`

`APA Annual Meeting
`Date/Place: May 14—18, 2016 / Arianta
`Abstract submission deadline: December 9, 2015 (midnight EST)
`
`Sponsorship: Sunovion Pharmaceuticals Inc. provided funding to support this research.
`
`CONFIDENTIAL
`
`LATUDAO4345463
`
`2
`
`